Device and method for decontamination / disinfection

Abstract

To provide devices for viral, microbial and pathogen control and removal.SOLUTION: A device comprises a carrier material comprising a carbohydrate-based polymer, and a binding agent. The binding agent is attached by one or more covalent bonds to the carrier material, and the binding agent can bind to a target, the target being one or more of a biotoxin, a virus, a microbe, and a microbial component.SELECTED DRAWING: Figure 3A

Description

[Technical Field]

[0001] The present invention relates to the field of virus, microorganism and pathogen control and elimination. [Background technology]

[0002] In the modern world, how to control the spread of viruses, bacteria, and other microorganisms and their components In particular, the extent to which such substances may be harmful to the health of humans or other organisms is a major issue. The transmission of these agents is a serious problem when they are harmful to the environment. This is often caused by the particles being transported through air or liquids. It is desirable to remove viruses, microorganisms and microbial components from these surfaces.

[0003] Pathogens must of course be particularly removed, but also a sterile environment must be maintained and chemical or industrial Harmless microorganisms are collected or removed for various purposes, such as to avoid contamination of industrial processes. It may be desirable to remove

[0004] Many of the techniques designed to remove microbial or viral attachments from surfaces are targeted For example, alcohol and other disinfectants, strong chemical disinfectants (generally oxidizing agents such as bleach, although reducing agents can be used) drugs), antibiotics, extreme heat, and radiation such as short-wave ultraviolet light and non-thermal (low-temperature) plasma. It is often used to destroy or denature viruses and microorganisms.

[0005] Such an approach has several major drawbacks, primarily the potential for variable efficacy. Microorganisms are resistant to almost all methods of sterilization. Some species of microorganisms may develop resistance to heat or other pathogens. They are able to produce spores that are highly resistant to chemical, pharmaceutical and ultraviolet attack. Many viruses, by their very nature, are difficult to destroy by standard means. Resistant to bacterial destruction, immune to antibacterial drugs such as antibiotics, and Biotoxins and components of microorganisms and viruses are designed to kill living organisms. They are likely to be resistant to mechanisms designed to combat them, making them difficult to remove. be.

[0006] Furthermore, the means used for disinfection may themselves be harmful to the user. This is true for most chemical disinfectants, but other methods such as antibiotics can induce allergic reactions. UV rays can damage the skin and cause cancer. In some cases, it may not be practical to apply such measures. It is not always feasible to heat the surface to high temperatures for this purpose.

[0007] Even if the target microorganism or virus is destroyed, e.g., lipopolysaccharides (endotoxins) Protein-based bacterial toxins such as erythropoietin and non-protein-based enzymes produced by Vibrio cholerae Harmful substances may remain, such as enterotoxins, which are produced by plants and animals. Similar concerns exist for other biotoxins such as:

[0008] Perhaps most importantly, chemical and antibiotic resistance has evolved by microorganisms and their descendants. and can even be transmitted horizontally by gene transfer. The use of strong chemical disinfectants and hygiene products is an additional risk factor, promoting mutations and increasing the risk of root Many important antimicrobial drugs, including the most powerful antibiotics and chemicals, No longer effective, increasing human (and animal) mortality rates, the threat of global pandemics and This is a concern for pathogens that pose a biological threat. Without appropriate control measures, they can cause widespread terror and damage to human and animal life. It may cause.

[0009] Therefore, biohazards, including those that may be resistant to standard removal and destruction methods, Remove toxins, viruses, microorganisms and microbial components for later analysis and / or disposal Therefore, there is a need to produce effective methods and devices to effectively retain these contaminants. There is.

[0010] Targeted biotoxins, viruses, microorganisms and microbial components are contained in a substance or carrier. Existing devices aim to remove biotoxins, viruses, and The interactions between the substance or carrier and the microorganisms and microbial components are generally not strong enough. These targets cannot be effectively retained. For example, the removed targets are simply material Or it may be adsorbed to the support, for example, by hydrogen bonding or similar interactions. These methods can result in inefficient uptake of the target or when the substance or carrier encounters another surface. Occasionally, the transiently bound target will be released.

[0011] The present invention provides a method for removing biotoxins, viruses, microorganisms and microbial components from contaminated surfaces. The present invention provides a device and method for removing granular particles and stably retaining them in a carrier material. Summary of the Invention

[0012] In a first aspect, the present invention provides a method for producing a composition comprising at least one carbohydrate-based polymer, and A device comprising a carrier material comprising a binder (e.g., a device for transporting gas or liquid from a surface and / or Suitable for the removal of biotoxins, viruses, microorganisms and / or microbial components from the body The binder is attached to the carrier material by one or more covalent bonds. and capable of binding to a target, the target being a biotoxin, a virus, a microorganism, and a microorganism. One or more biological components.

[0013] The carrier material may include cellulose as a carbohydrate-based polymer, one or more When the carrier material comprises cellulose, the binder may comprise one or more of: may be further covalently bound to the cellulose.

[0014] The device may contain a fluid in which the carrier material is dissolved, suspended, dispersed, emulsified, or otherwise carried. It may include.

[0015] Binding agents include antithrombotic agents, anti-inflammatory agents, antibodies, antigens, adhesins, immunoglobulins, enzymes, phosphatase inhibitors, and the like. Luminescence, neurotransmitters, cytokines, proteins, globular proteins, cell adhesion proteins Proteins, peptides, cell attachment peptides, proteoglycans, toxins, polysaccharides, carbohydrates, fatty acids , drugs, vitamins, DNA segments, RNA segments, nucleic acids, dyes and ligands In some embodiments, the binding agent may comprise one or more of a lectin, It may include one or more of glycoproteins, oligosaccharides, and glycoconjugates.

[0016] The binding agent may comprise a lectin, and the lectin may be AIA / Jacalin, RPbAI, A AL, ABL, ACA, AMA, BPA, CAA, Calcepa, CCA, ConA, CPA , DBA, DSA, ECA, EEA, GHA, GNA, GSL-I-B4, GSL-II , HHA, HPA, Lch-A, Lch-B, LEL, LTA, MAA, MOA, MPA , NPA, PA-I, PCA, PHA-E, PHA-L, PNA, PSA, RCA-I / 120, SBA, SJA, SNA-I, SNA-II, STA, UEA-I, VRA, V It can be one or more of VA-B4, WFA, and WGA. Cutin is a stimulator of VRA, Lch-B, EEA, PA-I, PNA, CAA, and GSL-I-B4. , AMA, RCA-I / 120, GNA.

[0017] In some embodiments, the binding agent may comprise a glycoprotein, wherein the glycoprotein is a glycoprotein. Romodulin (Tamm-Horsfall protein), fetuin, asialofe Chew, invertase, fibrinogen, alpha-1-antitrypsin, alpha-cris Talin, ceruloplasmin, α-1-acid glycoprotein, RNAse B, transferrin Phosphorus, β-lactoglobulin, C.-lactalbumin, albumin, B-casein, C -Casein, K-casein, lactoferrin, egg albumin, ovomucoid, ovotra The glycosaminoglycan may be one or more of: sphenesin, sphenesin, and derivative glycomacropeptide. Typically, glycoproteins include fetuin, asialofetuin, and α-crystallin. It may be one or more of phosphorus.

[0018] In some embodiments, the binding agent is a glycoconjugate or a neoglycoconjugate. or neoglycoconjugates, Blood Group A-BSA, Blood Group B-HSA, Fuc-α-4AP-BSA, Fuc-β-4AP-BSA, 2´Fukoshi Lactose-BSA, difucosyl-para-lacto-N-hexaose-APD-HSA (Lea / Lex), trifucosyl-Ley-heptasaccharide-APE-HSA, Nofucosyl, monosialyllact-N-neohexaose-APD-HSA, Gal-β -4AP-BSA, Galα1,3Gal-BSA, Gal-α-1,3Galb1, G al‐β‐1,4Gal‐BSA, Gal‐α‐1,2Gal‐BSA, 4GlcNAc -HSA, Gal-α-PITC-BSA, Gal-β-ITC-BSA, Glc-β- 4AP-BSA, Glc-β-ITC-BSA, GlcNAc-BSA, globotriolein Globo-N-tetraose-APD-HSA, Globo-N-tetraose-APD-HSA, Globotriose-APD- HSA, GM1-pentasaccharide-APD-HSA, Asialo-GM1-tetrasaccharide Saccharide-APD-HSA, globo-N-tetraose-APD-HSA, globo Lyose APD-HSA, H-type II-APE-BSA, H-type 2-APE-HSA, Ma n-α-1,3(Man-α-1,6), Man-BSA, Man-α-ITC-BSA , Man-b-4AP-BSA, LacNAc-BSA, LacNAc-α-4AP-B SA, LacNAc-β-4AP-BSA, Lac-β-4AP-BSA, Lacto-N- Tetraose-APD-HSA, Lacto-N-Fucopentaose I-BSA, Lacto- N-Neotetraose-APD-HSA, lacto-N-fucopentaose II-BSA , lacto-N-fucopentaose III-BSA, lacto-N-difucohexaose I-BSA, Lewis a-BSA, Lewis x-BSA, Lewis y-tet Lasaccharides-APE-HSA, LNDI-BSA / Lewis b-BSA, Di- Lex-APE-BSA, Di-Lewisx-APE-HSA, Tri-Lex-AP E-HSA, L-rhamnose-Sp14-BSA, 3´sialyllactose-APD- HSA, 3'-sialyl-3-fucosyllactose-BSA, 6'-sialyllactose- APD-HSA, Xyl-α-4AP-BSA, Xyl-β-4AP-BSA, 3´ shea 3´Sialyl Lewis x-BSA, 3´Sialyl Lewis a-BSA, 6-Sulfo Lewis x-BSA, 6-sulfo Lewis a-BSA, 3-sulfo L Lewis a-BSA, 3-sulfo Lewis x-BSA, sialyl-LNF V -APD-HSA, and sialyl-LNnT-penta-APD-HSA, or It could be more than that.

[0019] When the binder is a glycoconjugate, neoglycoconjugate, or glycoprotein, mannose, N -acetylglucosamine, N-acetylgalactosamine, N-acetylneuraminic acid, N -glycolylneuraminic acid (sialic acid), galactose, glucose, and fucose moieties The amino acid sequence may have terminal sugar residues, including one or more of the amino acid sequences.

[0020] The carrier material may further comprise an antimicrobial substance, which may be one of a disinfectant, an antibiotic, and a detergent. The antimicrobial agent may be silver, copper, or EDTA.

[0021] In any embodiment, the carrier material of the device may be a cloth, wipe, wound dressing, swab, or the like. The barrier layer may be in the form of a filter, pad, blanket, mat, mask or coating.

[0022] In a second aspect, the present invention provides a method for removing biotoxins, viruses, microorganisms and / or fungi from surfaces. Alternatively, a method for removing microbial components is provided, in which the method comprises using any of the methods described herein. providing a device according to an embodiment and contacting a surface with the device. nothing.

[0023] In a third aspect, the present invention provides a method for treating a bacterial infection comprising administering to a subject a biotoxin, virus, microorganism and / or microorganism. A method for removing biological components from a gas or liquid is provided, the method comprising: providing a device according to any of the embodiments described above, and passing a gas or liquid through the device; Includes:

[0024] In an embodiment of any of the above methods, the binding agent is a binding agent for the biotoxin, The viruses, microorganisms and / or microbial components that are removed can be bound to the and / or the microbial component may be a spore.

[0025] In a further aspect, the present invention provides a method for making a device, the method comprising: providing a carrier material comprising at least one carbohydrate-based polymer; with an oxidizing agent to generate acid and / or aldehyde groups; , such that the binding agent is linked to the carbohydrate-based polymer by one or more covalent bonds. contacting the cells with a binding agent comprising one or more of a lectin, a glycoprotein, and a glycoconjugate. The oxidizing agent is a periodate, preferably sodium periodate. The oxidizing agent is 2,2,6,6-tetramethylpiperidine-1-oxyl radical (TEMPO ), sodium nitrate or sodium nitrate in phosphoric acid; in the presence of organic solvents and bases activator tosyl chloride; and combinations thereof. .

[0026] Further potential features discussed in conjunction with embodiments of the device according to the present invention include the It is believed to apply equally to devices manufactured by the process.

[0027] In certain embodiments, a device is provided, the device comprising: a carrier material comprising cellulose; and a binding agent comprising a glycoprotein, the glycoprotein being uromodulin (Tamm-Ho rsfall protein), fetuin, asialofetuin, invertase, fibrinogen, α-1-antitrypsin, α-crystallin, ceruloplasmin, α -1-acid glycoprotein, RNAse B, transferrin, β-lactoglobulin, C.-lactalbumin, albumin, B-casein, C-casein, K-casein, La Transferrin, ovalbumin, ovomucoid, ovotransferrin, and derivatives The binder is selected from one or more of cellulose, cellulose copolymers ... The binding agent is capable of binding to the target, and the target is capable of binding to the bioagent. The pathogen may be one or more of a protoxin, a virus, a microorganism, and a component of a microorganism. [Brief explanation of the drawings]

[0028] The invention is further illustrated by reference to the accompanying drawings: [Figure 1A] FIG. 1A shows the results of efficacy tests using devices according to various embodiments of the present invention to remove Francisella tularensis from various surfaces. [Figure 1B] FIG. 1B shows the results of efficacy tests using devices according to various embodiments of the present invention to remove Francisella tularensis from various surfaces. [Figure 1C] FIG. 1C shows the results of efficacy tests using devices according to various embodiments of the present invention to remove Francisella tularensis from various surfaces. [Figure 2A] FIG. 2A shows the results of efficacy tests using devices according to various embodiments of the present invention to remove Clostridium botulinum from various surfaces. [Figure 2B] FIG. 2B shows the results of efficacy tests using devices according to various embodiments of the present invention to remove Clostridium botulinum from various surfaces. [Figure 2C] FIG. 2C shows the results of efficacy tests using devices according to various embodiments of the present invention to remove Clostridium botulinum from various surfaces. [Figure 2D] FIG. 2D shows the results of efficacy tests using devices according to various embodiments of the present invention to remove Clostridium botulinum from various surfaces. [Figure 3A] FIG. 3A shows the results of efficacy tests using devices according to various embodiments of the present invention to remove Bacillus anthracis in cellular (3A) or spore (3B) form from various surfaces. [Figure 3B] FIG. 3B shows the results of efficacy tests using devices according to various embodiments of the present invention to remove Bacillus anthracis in cellular (3A) or spore (3B) form from various surfaces. [Figure 4A] FIG. 4A shows the results of efficacy tests using devices according to various embodiments of the present invention to remove influenza virus from various surfaces. [Figure 4B]FIG. 4B shows the results of efficacy tests using devices according to various embodiments of the present invention to remove influenza virus from various surfaces. [Figure 4C] FIG. 4C shows the results of efficacy tests using devices according to various embodiments of the present invention to remove influenza virus from various surfaces. [Figure 5A] FIG. 5A shows the results of efficacy testing of devices according to various embodiments of the present invention in removing EHEC Escherichia coli (E. coli) O157:H7 and Enterobacter cloacae from various surfaces. [Figure 5B] FIG. 5B shows the results of efficacy testing of devices according to various embodiments of the present invention in removing EHEC Escherichia coli (E. coli) O157:H7 and Enterobacter cloacae from various surfaces. [Figure 6] FIG. 6 shows the results of efficacy testing of devices according to various embodiments of the present invention for removing Propionibacterium acnes from plastic surfaces. [Figure 7] FIG. 7 shows the results of an efficacy test using a device according to an embodiment of the present invention to remove Candida albicans from a plastic surface at various pH levels. [Figure 8] FIG. 8 illustrates the method of testing a device according to an embodiment of the present invention on a model of skin inoculated with various microorganisms. [Figure 9A] FIG. 9A shows the results of an efficacy test in which a device according to an embodiment of the present invention was used to remove E. coli from pig skin sections. [Figure 9B] FIG. 9B shows the results of an efficacy test in which a device according to an embodiment of the invention was used to remove E. coli from pig skin sections. [Figure 10] FIG. 10 shows the results of an efficacy study in which a device according to an embodiment of the present invention was used to remove Candida albicans from a section of pig skin. [Figure 11]FIG. 11 shows the results of an efficacy study in which a device according to an embodiment of the invention was used to remove Aspergillus fumigatus from a section of pig skin. DETAILED DESCRIPTION OF THE INVENTION

[0029] All references cited herein are incorporated by reference in their entirety. Unless otherwise defined, all technical and scientific terms used herein are intended to be limiting of the scope of the present invention. "Terms and conditions" have the same meaning as commonly understood by one of ordinary skill in the art.

[0030] Before further describing the present invention, definitions helpful to an understanding of the invention are provided.

[0031] As used herein, the term "target" refers to anything that is desired to be removed from a surface. of or that is incorporated or immobilized in / on the device of the present invention. Typically, the target is a biotoxin, virus, microorganism or microbial component, and is a pathogen. In some cases, the target may be an allergen, or a substance produced by non-microbial life. Microbial components that are present in the soil, such as plant pollen, fungal spores, dust mite feces and other components, nuts, Foods such as fish and shellfish, animal or plant toxins or poisons, and animal products such as dander It may be a potential allergen from food products.

[0032] As used herein, the term "microorganism" refers to a microorganism, particularly a bacterium, a fungus, a so-called By "protozoa" is meant "protozoa" or any other microscopic prokaryotic or eukaryotic organism.

[0033] As used herein, the terms "microbial component," "microbial product," or "microbial substance" refer to The term "microbiological product" refers to the microbial product that is desired to be removed from a surface or device of the present invention. Microbial components are toxins, i.e., those that are entrapped or immobilized in / on substances that are harmful to the body, such as protein-based or or non-protein-based bacterial toxins, or enterotoxic toxins, such as those produced by Vibrio cholerae. It may be a toxin.

[0034] As used herein, the term "toxin" or "biotoxin" refers to any substance that is effective against a substance in the body. Biotoxins are substances of harmful biological origin that are produced by microorganisms as described above. The nutrients may be derived from plants or may have other sources such as plants or animals.

[0035] As used herein, the term "pathogen" refers to a virus or pathogen capable of causing disease. or microorganisms.

[0036] As used herein, the term "carbohydrate-based polymer" refers to a polymer that is composed of monosaccharide units (monosaccharides). refers to polymers that contain sugar molecules as the main or only component of their repeating polymer units. Carbohydrate-based polymers include polysaccharides, dextrose, and cellulose, as further described below. starch, glycogen, fungal β-glucan, chitin, chitosan, cellulose and Cellulose derivatives (e.g., cellulose acetate, celluloid, and nitrocellulose) sucrose), laminarin, chrysolaminarin, xylan, arabinoxylan, mannan, fucoidan Such polymers include, but are not limited to, mannose and galactomannans. Although most of them consist only of monosaccharide units and their derivatives, copolymers containing monosaccharides and other units, e.g. Sugar-peptide hybrid copolymers exist. In addition, certain carbohydrate-based polymers - dissolving, suspending, dispersing, emulsifying, especially when they are non-fibrous or by other methods, sprays, sols, aerosols, elastomers, etc. into a fluid carrier such as a liquid or gas. It can be carried as a emulsion or other.

[0037] As used herein, the term "polysaccharide" refers to a chain of monosaccharide units (simple sugar molecules). refers to a carbohydrate-based polymer composed of a chain that may be linear or branched. Polysaccharides may be used after the synthesis, such as starch, glycogen, and laminarin. Other polysaccharides are cellulose, fungal β- Contains glucan, chitin, pectin, xylan, arabinoxylan, etc., and is used for structural purposes. Bacteria often produce and secrete polysaccharides, for example, which aid in adhesion to surfaces. These may help the virus evade the host's immune system.

[0038] As used herein, the term "cellulose" refers to D-glucose with a β(1→4) bond. Cellulose is a bio-carbohydrate polymer made from chains of cellulose units. It is used by green plants and other species, including some algae and some bacteria. Micronized cellulose or nanocellulose can be non-fibrous, so Dissolve, suspend, disperse, emulsify, or otherwise dissolve or dissolve in a liquid or gaseous form Carried in a fluid carrier as a spray, sol, aerosol, emulsion, or other It can be done.

[0039] As used herein, the term "binding agent" refers to a compound that binds to a biotoxin, virus, or microorganism. means a biological molecule capable of binding to a substance or microbial component. , antithrombotic agents, anti-inflammatory agents, antibodies, antigens, adhesins, immunoglobulins, enzymes, hormones, Transmitter, cytokine, protein, globular protein, cell adhesion protein, peptide peptides, cell adhesion peptides, proteoglycans, toxins, polysaccharides, carbohydrates, fatty acids, drugs, biosynthetic agents one or more of: a protein, a DNA segment, an RNA segment, a nucleic acid, a dye, and a ligand Typically, the binding agents discussed herein include glycoproteins, The sugars may be one or more of oligosaccharides, lectins, complex carbohydrates and their derivatives.

[0040] As used herein, the term "glycoprotein" refers to a glycoprotein having one or more glycoproteins attached thereto. This refers to proteins that have oligosaccharide groups or glycans. Many secreted proteins have Transmembrane proteins with extracellular domains are often "glycosylated" in this way. These domains often have sugar groups attached to them.

[0041] As used herein, the term "conjugate carbohydrate" refers to a carbohydrate having one or more glycoconjugates attached thereto. It refers to proteins and lipids that contain oligosaccharide groups of larger glycans. Examples include: glycoproteins, glycolipids, glycosphingolipids, proteoglycans and and glycosaminoglycans. "Neoglycoconjugates" or NGCs are , refers to artificial or synthetic glycoconjugates, especially glycoproteins and glycolipids, where proteins Alternatively, the lipid backbone is chemically linked to one or more sugar residues. Proteins such as bovine serum albumin (BSA) and human serum albumin (HSA) is used in the preparation of neoglycoconjugates.

[0042] As used herein, the term "lectin" refers to a carbohydrate-binding protein. (The terms carbohydrate-binding protein or CBP are used interchangeably.) The enzymes are specific for carbohydrate moieties, such as those found in glycoproteins, glycolipids, or oligosaccharides. Some lectins have the ability to agglutinate particles to which they bind. However, the term "agglutinin" does not refer to any specific antigens, such as antibodies. , can be applied to any substance that allows such aggregation.

[0043] As used herein, the term "adhesin" refers to a molecule that binds a cell to another cell or surface. These refer to cell surface components involved in adhesion. are used and are common in pathogenic, parasitic or commensal microorganisms.

[0044] As used herein, the term "antiseptic" refers to an agent having antibacterial activity, especially a bactericidal or destructive effect. means a chemical substance that kills or destroys or prevents their growth or reproduction. In general, antiseptics are safe for use on skin and living tissue, including areas such as the mouth, but are not effective. It is not commonly used internally due to toxicity and safety concerns. Disinfectants are effective in denaturing or destroying viruses. Alcohols, mild disinfectants such as bleach and peroxide, iodine, chlorhexidine gluconate Many classes of compounds, such as cyclohexylamines and some specific chemicals like quaternary ammonium compounds, There are disinfectants available.

[0045] As used herein, the term "antibiotic" refers to any substance that is used or is used internally. These substances often inhibit bacterial processes. It interferes with the process of microbial proliferation, causing the death or lysis of microbial cells, but is generally ineffective against viruses and bacterial products. Penicillins, cephalosporins, tetracyclines, ansamycins There are many well-known types of antibiotics.

[0046] The present invention relates to biotoxins, viruses, microorganisms and microbial-derived components (proteins, peptides, etc.). (peptides and carbohydrates) collection, decontamination / disinfection, preservation for peripheral diagnostic and forensic applications This paper describes the use of viral vectors and related devices and methods for delivery of viral vectors. targeting the natural binding sites of bacteria, microorganisms and / or their components, or biotoxins; A biological decontaminant used on physical and animal surfaces, as well as on the skin and mucosal epithelium of humans and animals. This method is broadly specific and provides a non-toxic, environmentally friendly alternative to dyes. , i.e., targeting multiple pathogens for multiple purposes in multiple formats. It is intended to be.

[0047] Interactions between cell surface proteins and carbohydrates are essential for cell-cell adhesion. Certain biotoxins, viruses, microorganisms and proteins of microbial origin can infect the host organism. This also applies to adhesion to other surfaces such as cells.

[0048] The mechanisms of attachment of microorganisms and viruses to cells are particularly important for commensal microorganisms. ), when symbiotic or parasitic microorganisms bind to host cells, This is an area of particular evolutionary importance. For example, host-bacterial interactions involve the attachment of cells to the host cell surface. Mediated by bacterial adhesins and their cognate glycan receptor epitopes. Gram-negative The majority of adhesins for both bacterial and Gram-positive bacteria bind to glycoproteins on the epithelial cell surface of the host organism. Identify suitable hosts via a marker (Kline et al., Cell Host and d Microbe, 2009). Each adhesin, target ligand, and tissue Examples of bacterial species that have these markers are shown in Table 1. In particular, in the case of pathogens, the correlation between the pathogen surface markers and those of the host is important. These interactions are essential for strong adhesion to the host, evasion of the immune system, and (in the case of intracellular pathogens and toxins) ) are crucial for accessing the interior of the cell. In fact, certain bacteria specifically The ability to adhere (often due to the possession of specific surface proteins or other molecules) is a factor in pathogenicity. These factors differentiate pathogenic and non-pathogenic strains. These substances always bind and retain before entering the cell and causing infection. and removed from the surface of human and animal cells.

[0049] [Table 1]

[0050] By using the same principle of carbohydrate-protein binding technology, the device can be used to bind carriers in a series of formats. Natural and modified protein and carbohydrate epitopes that are chemically linked to This allows for a unique approach. The device competes with the host's attachment surface. capable of binding to biotoxins, viruses, microorganisms and / or their components, Various "hooks" that can be used to remove or capture these targets quite effectively to provide.

[0051] Therefore, microorganisms and proteins of microbial origin (bacteria, viruses from these substances) immobilized on a physical material to remove bacteria (microbes, phage particles, fungi and proteins) The carbohydrates, proteins and protein fragments used to detect biotoxins, viruses, microorganisms Collect samples of organisms and / or their components, reduce the microbial load on surfaces, and clean surfaces. Decontaminate / disinfect and store samples collected on the device for diagnostic and forensic purposes can be done.

[0052] Carrier Substance The carrier material is the surface to which the binder is attached and the virus, microorganisms, microbial components and and / or provide a substrate onto which the biotoxin can be immobilized. Suitably the carrier material is a strong The compound can form a covalent bond with the binding agent so that the compound can be irreversibly linked by force. do.

[0053] Typically, the carrier is a starch, glycogen, chitin, cellulose, chitin, pectin, Preferably polysaccharides such as cellulose, cellulose, cellulose gum ... The carrier may preferably comprise cellulose. For example, the carrier may comprise cellulose, hemicellulose, or lignocellulose. may include those that essentially contain cellulose, such as paper, cotton, viscose, linen, etc. Or it can be made from plant-derived materials such as hemp, or the material can be made from cells of other origins. The carrier may also be a synthetic material or a cellulosic material. Blends of polyester-containing materials, such as a 50% blend of polyester material and cotton. Cellulose can also be produced by microorganisms such as bacteria. In particular, bacteria of the genus Acetobacter, Sarcinaventriculi, and Agrobacterium It is used in the production of cellulose.

[0054] Non-fibrous cellulosic materials and carbohydrate-based polymers can serve as carriers. In particular, micronized cellulose and nanocellulose are thus used to produce non-fibrous cellulose. Such non-fibrous cellulose or carbohydrate-based polymers can be used as a Polymers are substances that dissolve, suspend, disperse, emulsify, or otherwise carry fluids such as liquids or gases. Thus, the compounds can be bound to the binding agents described herein. When applied, such preparations may be in a non-solid form, such as a spray or paint. , can be applied to the receptor material.

[0055] Such non-solid formats of carbohydrate-based polymers linked to binders have been reported elsewhere. This allows for a range of applications that are not possible with conventional methods, for example, in suspension or soluble form. Such products / devices provide protection to said materials depending on the properties of the product applied. After application, the coating may be sprayed or otherwise applied to a receptor material such as a fabric. , the receptor material may be treated with, for example, a detergent or a low pH solution to remove previously applied products. The receptor material can then be re-treated with fresh product. This allows the protection to be restored before the next use or exposure. For example, in the processing of personal masks or other personal protective equipment, depending on the specific purpose, one or more of biotoxins, viruses, microorganisms, and / or microbial components It can be used to provide protection against

[0056] Further possible uses of carbohydrate-based polymers linked to binders in non-solid formats Uses include use as a cleaning composition, which is sprayed onto the receptive material to be cleaned. or otherwise applied, and then any conjugated target biotoxins, viruses, The bacteria, microorganisms, and / or microbial components may be removed together with the bacteria. Specific applications of the law include cleaning large shipping containers, shipping hubs and hospitals, and the cleaning of hospitals or and sterilization of instruments for aseptic applications such as in space.

[0057] More generally, and for all possible formats, the device of the present invention Permanently kills ingested biotoxins, viruses, microorganisms and / or microbial components If it is desired to denature, denature, or otherwise destroy the carrier or device, The carrier may further contain suitable agents for the purpose. For example, the carrier may contain antibiotics, antiseptics, bleaching agents, which may include hypochlorite, peroxide, and percarbonate, as well as silver, which has antibacterial properties or other materials such as copper, other suitable metal ions, and those shown to have antibacterial effects. Chemicals that are antibacterial or antiviral in nature, such as metal chelators such as EDTA It can be impregnated or mixed into the material (Finnegan and Perciva (Wound Healing Society, 2014). Other possibilities include Examples include benzoic acid, benzalkonium chloride, and other quaternary ammonium cations. Depending on the proposed use of the device, different additional substances can be selected. For example, if the device is intended for use on the skin, it must be safe for such use. A safe disinfectant can be selected. Stabilizers and / or preservatives can also be used. , examples of which are known in the art.

[0058] In some cases, target biomarkers may be used for subsequent analysis for research, diagnostic or forensic purposes. It may be desirable to retain iotoxins, viruses, microorganisms and / or microbial components. In such cases, the carrier can be substantially free of antibacterial substances, and the immobilized containing buffers or other solutions or specific pH levels to support the targeted target. and / or by extracting target biotoxins, viruses, microorganisms and / or They may also be further processed to increase the likelihood that the microbial components remain intact. Since most interactions depend on the aqueous environment, specific pH levels, etc., the desired target of the binding agent A buffer or other solution may also be included to aid in binding to the antibody.

[0059] It is envisioned that the carriers may be prepared in many different forms, e.g., wipes, cloths, wound dressings, etc. , filters, pads, coatings, blankets, mats, masks and other articles are It can be constructed with a quality, especially in the form of a wipe similar to tissue, towel, or napkin. This is done by wiping the surface to be decontaminated and then discarding it. The device of the present invention is also advantageous in that it can be suspended in air, for example. or from gas or liquid, such as when removing aerosolized virus particles. used to remove harmful biotoxins, viruses, microorganisms and / or microbial components. In this case, the carrier may be capable of removing the target. It is designed to allow gas or liquid to pass through. The material is combined with the binder and dissolved, suspended, dispersed, emulsified, or otherwise carried in the fluid. It is also contemplated that fluids containing such carrier materials may be used in the device of the present invention. Here is an example of a chair.

[0060] The device of the present invention may also be used for general cleaning of biological or non-biological surfaces, such as the skin. As a result, the carrier should be suitable for its intended use. ingredients such as cleansers, moisturizers, deodorants or chemicals for makeup removal (e.g. e.g., when used for cleaning skin) and / or dust from non-biological surfaces May contain detergents, fragrances, or cleaning agents for the removal of grime, metal tarnish, etc. In this way, the devices described herein can be used to treat body surfaces and skin Removes or kills pathogens from the skin (e.g., acne, diaper rash, and other skin conditions) It can be used for therapeutic purposes, such as to treat various conditions (e.g., inflammatory bowel disease, ulcers, and ulcers), as well as for non-therapeutic purposes, such as cosmetic applications. In practical applications, the device is used for skin cleansing or moisturizing, baby care, hand washing, makeup removal, It can be used for applying a cleanser or deodorant.

[0061] Incontinence pads incorporating or including the devices of the present invention are also contemplated and may be used to promote urinary tract disease. The composition can be selected to provide protection against infectious agents of interest.

[0062] Pads and / or wipes designed for breastfeeding and / or nipple care also It is intended to be effective in providing protection against infectious pathogens that cause mastitis. It can be designed to do so.

[0063] Binder capable of binding to target biotoxins, viruses, microorganisms and / or microbial components A binding agent that binds to a biotoxin, virus, microorganism, or microbial agent is attached to a carrier material. Any biologically derived molecule capable of binding to a biological component can be used in the devices of the present invention. Such molecules can be used in the treatment of thrombotic disorders, anti-inflammatory disorders, antibodies, antigens, and the like. Adhesins, immunoglobulins, enzymes, hormones, neurotransmitters, cytokines, proteins , globular proteins, cell adhesion proteins, peptides, cell adhesion peptides, proteoglycans amino acids, toxins, polysaccharides, carbohydrates, fatty acids, drugs, vitamins, DNA segments, RNA segments The compound may comprise one or more of a marker, a nucleic acid, a dye, and a ligand. The one or more binding agents may include glycoproteins, oligosaccharides, lectins, and glycoconjugates. nothing.

[0064] Binders suitable for use in the present invention have many sources, many of which are derived from milk, urine, mucus, saliva, etc. They can be derived from naturally occurring solutions such as liquids, eggs, fungi, algae and plant extracts. Binding agents may also be produced synthetically (e.g., by in vitro translation) or genetically modified. Engineered (e.g., recombinantly engineered) or naturally produced binding agents can be used to bind specific peptides. For example, to generate peptides, glycopeptides, fragments, glycans, or the like, specific They can be engineered or modified to display only the binding portion of a larger molecule.

[0065] Another advantage of many of the binders discussed here is that they are commonly used antimicrobials. It is non-toxic and environmentally friendly compared to biocidal or antiviral reagents. Polyguanidine compounds, which are often used as antimicrobial agents, have been shown to be toxic to humans and to cause environmental damage. It is in a category of compounds restricted by the FDA due to its potential to cause An example of a guanidine is chlorhexidine gluconate, and from now on this compound will be available by prescription only. There are plans to limit the use of quaternary ammonium compounds such as polyionenes. The compound is commonly used in wipes and hand sanitizers, but the FDA is in the process of restricting its use.

[0066] Some potential binding agents are highly specific for only one target (especially antibodies). Although most are expected to bind to one or more of the following, many have a broader range of potential binding targets. Used for the removal of targeted biotoxins, viruses, microorganisms and / or microbial components However, this increases the number of potential targets and thereby limits the use of the device. Multiple types of binders can be used in one device to improve usability. It may be from the same class of molecules (e.g., glycoproteins from multiple species) or from different classes. (e.g., glycoproteins and lectins). Thus, the device according to the invention can be used for highly specific detection, for example in a research or forensic setting. or for more general use suitable for indoor or outdoor situations. It can be manipulated to have a use.

[0067] Biotoxins, viruses, microorganisms and / or microbial components in combination with host cells or Many interactions between the surface to which they adhere involve carbohydrates, glycoproteins, and lectins ( Carbohydrate-binding proteins or CBPs, glycan-binding proteins or GBPs) and their These fragments (peptides, etc.) are responsible for the production of virulence factors. For example, certain strains of E. coli The type 1 fimbrial FimH adhesin found in certain bacteria, such as the Streptococcus aureus (STI), binds to CD48, TLRs, and HIV-1. 4, or more generally, its lectins (carbohydrates It can bind to mannose residues via its nucleotide-binding domain.

[0068] Therefore, glycoproteins, glycolipids, glycosphingolipids, proteins of natural or synthetic origin Glycoconjugates, including glycosaminoglycans and glycosaminoglycans, are the target of biotoxins and viruses. providing binding sites for adhering the microorganisms, microorganisms and / or microbial components to the device; The glycoconjugates for use in the device according to the present invention are believed to be N-acetylglucosamine, N-acetylgalactosamine, N-acetylneuraminic acid sialic acid, galactose, glucose, and terminal residues containing one or more fucose moieties.

[0069] Suitable glycoconjugates and neoglycoconjugates for use in the devices of the present invention include Blood G roup A-BSA, Blood Group B-HSA, Fuc-α-4AP-B SA, Fuc-β-4AP-BSA, 2´fucosyllactose-BSA, difucosyl-PA La-lacto-N-hexaose-APD-HSA (Lea / Lex), Trifucosyl-L ey-heptasaccharide-APE-HSA, monofucosyl, monosialyllact-N- Neohexaose-APD-HSA, Gal-b-4AP-BSA, Galα1,3Ga l-BSA, Gala1,3Galb1, Galb1,4Gal‐BSA, Galα1, 2Gal‐BSA, 4GlcNAc‐HSA, Gal‐α‐PITC‐BSA, Gal‐ β‐ITC‐BSA, Glc‐b‐4AP‐BSA, Glc‐β‐ITC‐BSA, Gl cNAc-BSA, globotriose-HSA, globo-N-tetraose-APD-H SA, globotriose-APD-HSA, GM1-pentasaccharide-APD-HS A, Asialo‐GM1‐tetrasaccharide‐APD‐HSA, globo‐N‐tetrasaccharide ose-APD-HSA, globotriose-APD-HSA, H-type-II-APE-BS A, H-type 2-APE-HSA, Manα1,3(Manα1,6), Man-BSA, M an-α-ITC-BSA, Man-b-4AP-BSA, LacNAc-BSA, La cNAc-α-4AP-BSA, LacNAc-β-4AP-BSA, Lac-β-4A P-BSA, lacto-N-tetraose-APD-HSA, lacto-N-fucopentaose I-BSA, lacto-N-neotetraose-APD-HSA, lacto-N-fucope N-fucopentaose II-BSA, lacto-N-fucopentaose III-BSA, lacto- N-Difcohexaose I-BSA, Lewis a-BSA, Lewis x-BS A, Lewis y-tetrasaccharide-APE-HSA, LNDI-BSA / Lew is b-BSA, Di-Lex-APE-BSA, Di-Lewisx-APE-HS A, Tri-Lex-APE-HSA, L-rhamnose-Sp14-BSA, 3´ sialic acid Lactose-APD-HSA, 3´Sialyl-3-fucosyllactose-BSA, 6´ -Sialyllactose-APD-HSA, Xyl-α-4AP-BSA, Xyl-β-4 AP-BSA, 3´ sialyl Lewis x-BSA, 3´ sialyl Lewis a -BSA, 6-sulfo Lewis x-BSA, 6-sulfo Lewis a-BSA , 3-sulfo Lewis a-BSA, 3-sulfo Lewis x-BSA, sialic acid Sialyl-LNF V-APD-HSA, and Sialyl-LNnT-penta-APD-HSA Includes:

[0070] Glycoproteins suitable for use in the devices according to the invention may contain one or more mannose, N-acetylglucosamine, N-acetylgalactosamine, N-acetylneuraminic acid, N-glycolylneuraminic acid (sialic acid), galactose, glucose, and fucose Such glycoproteins and oligosaccharides may have terminal residues containing amino acid moieties. Derived from naturally occurring solutions such as milk, urine, mucus, saliva, eggs, fungi, algae and plant extracts Specific glycoproteins suitable for use in devices according to the present invention include uromodilution. urin (Tamm-Horsfall protein), fetuin, asialofetui invertase, fibrinogen, α-1-antitrypsin, α-crystallin , ceruloplasmin, α-1-acid glycoprotein, RNAse B, transferrin, B-lactoglobulin, C-lactalbumin, albumin, B-casein, C-casein Insulin, K-casein, lactoferrin, egg albumin, ovomucoid, ovotransferase Mucins are high molecular weight proteins and include glycomacropeptides, glycoproteins, and glycoprotein derivatives. Other glycoproteins found in mucus are also used. These components of mucus can interfere with the adhesion of microorganisms and prevent the formation of biofilms. This is thought to reduce the risk of infection (Caldara et al., Curren t Biology, 2012).

[0071] Lectins, carbohydrate-binding proteins, help bacteria and viruses bind to their intended targets. Involved in cell-cell interactions and in the innate and adaptive immune response Lectins are present in all living organisms and play important roles in cell adhesion, immune recognition, and microbial recognition (pathogen recognition). They play various roles in host recognition, toxin activity, and plant protection (e.g., for host and symbiont organisms). Research has shown that many lectins can be effectively isolated from plant and fungal species. Lectins can bind to complex carbohydrates and can be engineered to change their specificity. Lectin-histochemistry is used to purify and characterize biospecimens under different conditions. Stain cells, tissues, and organs to understand differences in glycosylation on different substrates.

[0072] Lectins contemplated for use in the present invention, and their sources, include, but are not limited to: Including but not limited to: AIA, Jacalin, (Artocarpus integrifolia) Jack fruit Fruit lectin; RPbAI, (Robinia pseudoacacia), false locust alectin; AAL, (Aleuria aurantia), orange peel fungus lectin; ABL (Agaricus bisporus), an edible mushroom lectin; ACA, (Amaranthus caudatus), amaranthin lectin; AMA, (Arum maculatum), Rose and Lady's Lectin; BPA, (Bauhinia purpurea), camel's foot tree lectin; CAA (Caragana arborescens), giant caramel lectin; Calsepa, (Calystegia sepium), bindweed lectin; CCA, (Cancer antennarius), California crab; ConA, (Canavalia ensiformis), jack bean lectin; CPA, (Cicer arietinum), chickpea lectin; DBA, (Dolichos biflorus), horsegram lectin; DSA, (Datura stramonium), jimsonweed lectin; ECA, (Erythrina cristagalli), Cock's kelp / Coral tree Kuching; EEA, (Euonymus europaeus), spindle tree lectin; GHA, (Glechoma hederacea) oyster lectin; GNA (Galanthus nivalis), snowdrop lectin; GSL-I-B4, (Griffonia simplicifolia), Griffoni A / Bandira bean lectin-I; GSL-II, (Griffonia simplicifolia), Griffonia / Bandilama lectin-II; HHA, (Hippeastrum hybrid), Amaryllis agglutinin; HPA, (Helix pomatia), small apple snail lectin; Lch-A, (Lens culinaris), lentil lectin A; Lch-B, (Lens culinaris), lentil lectin B; LEL, (Lycopersicum eculentum), tomato lectin; LTA, (Lotus tetragonolobus), Lotus lectin; MAA, (Maackia amurensis), dogwood agglutinin; MOA, (Marasmius oreades), fairy ring mushroom lectin; MPA, (Maclura pomifera), American halibut lectin; NPA, (Narcissus pseudonarcissus), Dafodyl lectin ; PA-I, (Pseudomonas aeruginosa), Pseudomonas aeruginosa lectin; PCA (Phaseolus coccineus), Scarlet Runner Bean Lek Chin; PHA-E (Phaseolus vulgaris) common bean hemagglutinin; PHA-L (Phaseolus vulgaris) Phaseolus vulgaris; PNA, (Arachis hypogaea), peanut lectin; PSA, (Pisum sativum), Pea lectin; RCA-I / 120, (Ricinus communis), castor seed lectin I; SBA, (Glycine max), soybean lectin; SJA (Sophora japonica), pagoda tree lectin; SNA-I, (Sambucus nigra), elderberry lectin-I; SNA-II, (Sambucus nigra), elderberry lectin-II; STA, (Solanum tuberosum) potato lectin; UEA-I, (Ulex europaeus), gorse lectin-I; VRA (Vigna radiate), mungbean agglutinin; VVA-B4, (Vicia villosa), hairy vetch lectin; WFA, (Wisteria floribunda), Japanese wisteria alectin; and WGA, (Triticum vulgaris), wheat germ agglutinin

[0073] adjustment In theory, it is possible for the binder to be relatively simply impregnated into the carrier material, but e.g. , by immersing the carrier material in an aqueous solution containing a binder, so that the binder is absorbed or adsorbed onto the carrier. The coupling of the binder to the carrier material is thereby achieved by forming a chemical bond, particularly a covalent bond, between the two. Such a relatively strong and permanent bond is created when the binder It does not dissipate over time and targets biotoxins, viruses, and microorganisms. Biological and microbial components are more strongly retained on the device / carrier material and less likely to migrate to the next surface. Without wishing to be limited by theory, it is believed that the carrier material may contain a binder. The stronger the binding, the more likely it is that the target will be taken up rather than the binder itself being removed from the support. It is also thought that the possibility of adhesion to the carrier increases. Covalent bonding to the polymer improves device safety, efficacy, stability and longevity. To rise.

[0074] The binder attached to the carrier material can be provided or formulated in any suitable manner. For example, a binder may act as a diluent, and / or excipient or stabilizer in a buffer solution. The binder can be used in solutions, rinses, shampoos, sprays, lotions, etc. One of the following: gels, foams, lubricants, creams, ointments, soaps, non-soap bars, and powders. Alternatively or additionally, in a form containing a pharmaceutically acceptable vehicle which may contain 1 or more may be provided to.

[0075] chemically treating the support material to form a covalent bond between the binder and the support material; It may be convenient to provide binding sites for binding agents, for example if the carrier material is cellulose If the cellulose contains cellulose, it can be treated to produce acid and / or aldehyde functional groups. This allows it to react with the amino groups of proteins, creating bonds. In these carrier treatment reactions, carbohydrate rings within the cellulose are cleaved by an oxidizing agent. In particular, the oxidizing agents used are perhalogenates, such as periodates or perchlorates, It could be carbonate, permanganate, hypochlorite, perborate, or peroxide. Other oxidation methods include TEMPO (2,2,6,6-tetramethylpiperidine). Oxidation of cellulose using the -1-oxyl radical; sodium nitrate in phosphoric acid and and / or oxidation with sodium nitrite; and / or organic solvents (acetone / dioxane etc.) and the activating agent tosyl in the presence of a base (such as pyridine or triethylamine) For example, treatment with toluenesulfonyl chloride is described in See, for example, US 5,516,673; Cumpstey I. "Many Chemical Modification of Sugars” ISRN Org Chem. 2013 Sep 10;2013:4 17672; Saito T, Isogai A. "TEMPO of natural cellulose" "Mediated Oxidation." Effect of Oxidation Conditions on the Chemical and Crystal Structure of the Water-Insoluble Fraction. 200 4;5(5):1983-1989; and Kim UJ et al., "The overproduction of crystalline cellulose" Iodate oxidation." Biomacromolecules. 2000;1(3):488 ‐492.

[0076] The purpose of such treatment is to introduce reactive groups into the cellulose molecule, which For example, aldehydes, ketones, N-hydroxysuccinimides, epoxides, imides The reaction can be one or more of the following: ester, anhydride, or carbonate. Reactions 1 and 2 are For example, sodium periodate opens the D-glucose units in the β(1-4) linkages of cellulose. Reaction 1: Formation of an active aldehyde group by the ring, followed by lectins, glycoproteins, This reaction (Reaction 2) involves the binding of proteins such as neoglycoconjugates. This reaction occurs at pH 5-9. The assay can be performed in a range of buffers (Figure 7). [ka]

[0077] In the example below, there is a Schiff base between the cellulose unit and the bound protein. '(-CH=NH-) is created. Optionally, to improve the permanence of the linkage, The double bond of the compound can be reduced to a single bond. This is achieved by the reaction of sodium cyanoborohydride. This reaction can be achieved by the use of reducing agents such as C. It can also be reduced to H2OH.

[0078] Such reactions form irreversible and highly stable bonds, linking the desired carbohydrates and Similar reactions can be used to embed sugars and proteins into cellulosic materials. Polymers, multimeric proteins and other biopolymers can be attached, where Amide or carboxylic acid bonds are used for conjugation. These reactions target sugar monomers. Considering this, a similar method was used to analyze starch, glycogen, laminarin, fungal β-glucan, and Lucan, chitin, pectin, xylan, arabinoxylan, dextran or amylose It will be appreciated that the binder can be attached to other sugar-containing carriers, such as polysaccharides containing sugars. For example, dextran has been oxidized and subsequently conjugated with soybean peptides (Wan et al., 2004). g and Xiong, J Food Sci Technol, 2016). Pep Other sugar-containing polymers such as tidoglycans (such as those found in bacterial cell walls) also form bonds. It can be a substrate to which the drug combination can be bound.

[0079] Methods such as those described, which involve oxidation of cellulose to which a binder is subsequently attached, result in It can also be appreciated that this method is preferable to methods involving modification of the combined reagents themselves, which include: Such treatments may impair or destroy the binding potential of these reagents. The methods described herein preserve the carbohydrate (or other) chemistry of the binder, and Similarly, the long life of the covalent bond ensures that the chemical This has advantages over methods that rely on electrostatic attraction or other forces to bind chemicals to carrier materials. Such bonds can deteriorate over time.

[0080] To promote the long-term stability and sterility of the device of the present invention, a carrier material, a carrier solution, The produced materials and / or packaging materials are subjected to filtration, heat, chemicals, irradiation and high pressure. The combination of the above can be used before, during or after the preparation steps, for example: Pasteurization, autoclaving, gamma irradiation, ultraviolet irradiation, electron beam (eBeam irradiation) , gas steam sterilization (ozone, chlorine dioxide, ethylene oxide, oxides of nitrogen) or similar Some of the techniques include:

[0081] Similarly, borate, Tris, and Chloride are used to promote long-term device stability and sterility. Buffers such as acetic acid buffers may be used and are known to be ophthalmically safe. This is an additional advantage.

[0082] Targeted biotoxins, viruses, microorganisms and microbial components The device of the present invention is capable of detecting biotoxins, viruses, microorganisms, and other pathogens associated with biothreat hazards. It is possible to target biological and / or microbial components, i.e., as in the case of bioterrorism. Potential hazards from biological weapons, synthetic biological products, and / or weaponized microbial components , or influenza variants, SARS, MERS, Hantavirus, Nipah virus Targeting potential pandemic pathogens such as Ebola virus, Zika virus, etc. Devices for such targets must have the necessary hardware to defend against these dangers and The device includes wipes and filters that can be used to remove the The company may also use the information for general research or for other purposes such as the production of vaccines or antitoxins. It can also be used in studies of defense against various agents. The method can be used in the context of biosurveillance, for example to capture or capture persistent biothreat pathogens after a natural outbreak or during a natural outbreak screening or prevention against pandemic and foodborne pathogens. These materials can be used for forensic, biosurveillance or other purposes. Since it is often important to positively identify the target, the device of the present invention is primarily It is not aimed at destroying them, but rather at removing them. It is advantageous to have such biothreat hazards and the factors that cause them. Examples of species considered include Francisella (tularemia), Bacillus anthracis (anthrax), and botulinum Bacteria such as Clostridium botulinum (botulism), Clostridium malayi (glanders), and Clostridium pseudomallei (melioidosis), as well as influenza Luenza virus, Ebola virus, Marburg virus, Variola major virus (smallpox ), foot-and-mouth disease virus (aphthovirus), SARS-associated coronavirus, Chaparé Viruses such as Lujo virus (Q fever caused by Coxiella genus, Arenaviridae family); and These include toxins such as botulinum neurotoxin, ricin, abrin, and Shiga-like toxins. Severe acute respiratory disease, also known as 2019 novel coronavirus (2019-nCoV) SARS-CoV-2 is a pandemic coronavirus disease The coronavirus strain that causes COVID-19 may be a target of embodiments of the present invention. A surrogate strain is a strain that resembles a biothreat pathogen in one or more ways. It is a species that is used as a mimic to study different strategies for combating biothreats. can be used as a surrogate and in the device as described herein. Examples of species that can also be targeted include Bacillus species (Bacillus subtilis, Atrophaeus, Mycobacterium tuberculosis ... Clostridium sporogenes; and Francisella tularensis, Francisella tularensis subsp. LV Contains S.

[0083] Target bacteria also cause healthcare-associated infections (HAIs), healthcare-associated infections (HCAIs), and hospital-acquired infections. pathogens that cause disease and / or antibiotic-resistant organisms that resist destruction by common antibiotics Examples of such bacteria include Clostridium difficile and Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant, yellow Staphylococcus aureus (VRSA), Escherichia coli (STEC, VTEC, EHEC), Clostridium Clostridium difficile, Klebsiella pneumoniae, Acinetobacter Bacter spp., Pseudomonas aeruginosa, Enterococcus faecalis, nontuberculous mycobacteria, Mycobacterium tuberculosis These bacteria include Proteus fortuitum, Proteus mirabilis, etc. The clear advantage lies in the mechanisms these bacteria use to destroy or evade antibiotics. Adhesion is not affected.

[0084] A further advantage of the present invention is that it can be effective in eliminating bacterial spores. As such, the spores produced by certain microorganisms are resistant to heat, chemical, pharmaceutical, and ultraviolet attacks. It has extremely strong resistance to the elements, so it is very difficult to destroy it. The adhesion method used by the present invention does not necessarily attempt direct destruction of the spores. has proven effective in eliminating such targets.

[0085] Targets include biotoxins, viruses, microorganisms and microbial components associated with foodborne illness. Many of these targets are Campylobacter, Clostridium, E. coli, Listeria, Salmonella, Shigella, Staphylococcus, Vibrio, Helicobacter Bacteria such as Helicobacter pylori, Norovirus (Norwalk Virus), Rotavirus Viruses such as foot-and-mouth disease virus can also be targeted. Can be used to decontaminate food preparation surfaces and utensils, or to clean mats, napkins, etc. It can be used as.

[0086] It is also conceivable that microbial components, such as bacterial toxins, may be targeted by the devices of the present invention. Such toxins include, for example, cholera toxin, botulinum toxin, pertussis toxin, enterotoxin, These include toxins, tetanus toxin, and staphylococcal enterotoxins. Biotoxins of plant or animal origin, such as cin, ricin, and abrin, are useful in the preparation of the present invention. As an example, the highly toxic ricin protein is a potential target for the device. The A chain is a dimer that acts as an N-glycoside hydrolase and is the basis of its toxicity; It has a B chain, a lectin that can bind to galactose residues on the surface of target cells, and is involved in cell invasion. The use of the device according to the present invention allows the incorporation of a substance that interacts with B-chain lectins. Those with specific binding agents that can remove or otherwise bind these proteins Some other toxic proteins, such as abrin, are effective at capturing or trapping toxic molecules. has a similar lectin component and can therefore also be targeted. In this context, the present invention provides This is advantageous compared to existing antimicrobial methods because toxins cannot be killed like microorganisms. and often can be resistant to modification by chemical or other means. The adhesive technique allows for the removal of toxins without these problems.

[0087] Tables 2 and 3 show the known associations of various bacterial toxins with the top 10 lectins. Specific interactions (Table 2), and glycoprotein / neo complexes determined based on binding analysis The carbohydrates are shown in Table 3. These analyses were performed using various lectins and glycoproteins / neoglycoconjugates. The evaluation of selected toxins against the quality of these proteins was performed by glycan microarray. This technique is a tool for evaluating protein-carbohydrate interactions in vitro. This allows for an increased number of experiments possible with limited sample amounts, and the subsequent focus Facilitate profiling or screening prior to tailored investigations (Kilcoy ne, Gerlach, Kane and Joshi, Analytical Methods, 2012).

[0088] [Table 2]

[0089] [Table 3]

[0090] The devices of the present invention can be used in a variety of applications, for example, prophylactically, therapeutically, and topically. Potential uses include decontamination, cleaning, sampling, sample retention, sample concentration, etc. shrinkage, forensic analysis of specimens, wound care and healing, prevention of disease transmission and spread, prevention of cross-contamination Prevention, prevention of biofilm formation, personal hygiene, and / or risk associated with infectious pathogens These include a reduction in stress and fear associated with the disease.

[0091] The devices of the present invention can also be used to treat or prevent certain conditions and diseases. Methods are also provided, including the use of a bacterial, fungal, viral or toxin-inhibiting agent, or a malarial parasite. Eukaryotic microorganisms such as Leishmania and sleep parasites such as Trypanosoma These include human, animal and plant diseases that can be transmitted by target microorganisms or or microbial components may cause skin diseases and disorders.

[0092] Examples of skin diseases and disorders caused by fungal pathogens and their underlying causes Possible species include Candida albicans, Pityriasis or ringworm (Malassezia fur or Pityrosporum orb) iculare), seborrheic dermatitis (Malassezia spp.), athlete's foot (tinea pedis, This is true for fungal species including Trichophyton, Epidermophyton, and Microsporum. Other infectious diseases and the resulting Pathogens that are thought to be involved include Propionibacterium vulgaris ( rium acnes, Propionibacterium granulosum and Pseudomonas aeruginosa), Staphylococcal scalded skin syndrome Group, impetigo, ecchyma, folliculitis, furuncles, carbuncle pyoderma (Staphylococcus aureus, Streptococcus pyogenes, Pseudomon aeruginosa), common body odor (Propionibacterium Staphylococcus aureus, Agalactiae, Streptococcus bovis, and Colon bacillus Bacillus subtilis, Pseudomonas aeruginosa, Streptococcus uberis and Staphylococcus aureus It also treats inflammation of the mammary gland tissue (mastitis) mediated by the HIV chromogenem. This may be done through the skin to aid in treatment or through the surface to reduce transmission. Devices can be manufactured that aim to eliminate these pathogens. is a chemical that is used to remove targeted biotoxins, viruses, microorganisms or their components. The device of the present invention can be applied to affected or at-risk skin for treatment or A method of protection against wound infection is also contemplated; Target viruses, microorganisms, or microbial pathogens from the skin or future wound site (e.g., from surgery) Removal of the body prevents colonization of the wound by opportunistic infectious agents. do.

[0093] It is also conceivable that the targets of such devices as described may be within body cavities. For example, the target biotoxin, virus, microorganism, or microbial component may Causes oral maldevelopment, disease or disorders such as gingivitis, periodontitis, tooth decay or halitosis (bad breath) Targeted biotoxins, viruses, microorganisms or microbial components can cause vaginal infections. The device of the present invention can treat or prevent infections. For this purpose, it can be applied in and around such cavities.

[0094] Pathogens involved in causing sexually transmitted diseases that may be targeted by the device of the present invention include gonorrhea, Bacteria, Chlamydia trachomatis, Treponema pallidum, Ureaplasma urealyticum, Includes chancroid bacteria.

[0095] Diseases involved in causing eye infections that can be targeted by the device according to the present invention Active ingredients include Staphylococcus spp., Neisseria gonorrhoeae, and Chlamydia trachomatis.

[0096] Pathogens involved in causing upper respiratory tract infections that may be targeted by the device of the present invention include: Aspergillus, Streptococcus pneumoniae and other Streptococcus species, Pseudomonas aeruginosa, Bordetella pertussis, Moraxella talaris, Mycoplasma pneumoniae, Mycobacterium tuberculosis, Coxiella burnetii, Klebsiella pneumoniae, Staphylococcus aureus , Legionnaires' disease bacteria, Escherichia coli, Proteobacteria such as Proteus and Serratia, Influenza, influenza virus, rhinovirus and SARS, MERS and and coronaviruses such as pandemic SARS-CoV-2.

[0097] The device of the present invention also removes biofilms from the target surface, i.e., from each other and from the surrounding tissue. It is intended to be used to remove clumps of microorganisms that adhere to surfaces. Ophyllum is a type of microbial organism that is highly susceptible to bacterial attack due to the number of organisms and the presence of extracellular factors that can protect the organisms from attack. It can be difficult to remove by conventional means.

[0098] The described devices also provide therapeutic and cosmetic applications between surfaces, including the skin. beneficial, commensal, probiotic, non-harmful and symbiotic bacterial and / or microbial components; and / or biotoxins in controlled doses. In such cases, a binder capable of binding to a probiotic target is added to a carrier substance. and a multilayer of probiotic microorganisms or microbial components is attached to the selected In this way, the device can attract beneficial microorganisms (probiotics) and release them onto a surface. and probiotic organisms) and combine them with other can be used to migrate, implant and / or deliver to a site or surface, Examples of such delivery include internal delivery to the gastrointestinal tract. Microorganisms that can be attached to the device of the invention but replication can still occur and subsequently produced The ions are not bound and can be freely transported to the target surface. Similar techniques are useful for subsequent use. It may allow for the collection and / or preservation of bacteria for this or other purposes (e.g., forensic analysis). or laboratory use) The biological components can be modified, for example, by changing the pH or ionic strength, or by using weak acids. By using a buffer, it may even be possible to separate the glyco- Disrupt protein interactions, thereby preventing the release of bound biotoxins, viruses, and microorganisms Alternatively, a monosaccharide or disaccharide solution can be used to release the microbial components.

[0099] Additionally, the devices of the present invention may be bonded by a bonding agent as contemplated herein. If possible, capture of targets that are not strictly biotoxins, viruses, microorganisms, or microbial components They can also be used to capture or remove allergens produced by non-microbial life. The lactic acid bacteria and other minor components may be bound by a binder as described. For example, plant pollen, fungal spores, dust mites, etc. feces and other components of animals, potential allergens from foods such as nuts and shellfish, or plant venoms or poisons, as well as animal products such as dander. Unwanted targets may cause allergic reactions or may be otherwise harmful to humans or animals. Allergic reactions are often mediated by cell-surface interactions, and some Since the allergens in this category contain or consist of complex carbohydrates, the device of the present invention is Advantageously, this can be useful for binding targets such as surfaces, liquids or The gas may be removed from the face or skin of the subject. For example, a device prepared to provide binding sites for plant pollen can be used to attach the pollen to a surface or or to remove pollen from the eyes or skin of humans or animals.

[0100] In an epidemic or pandemic situation, the present invention includes, but is not limited to: It has a variety of uses: reducing the risk of transfer when removing personal protective equipment (PPE) decontamination of exposed skin for sampling and cleaning up the PPE itself; and future decision-making (such as imposing lockdowns, eliminating public access and transport units) ) collection of samples from the public (e.g. during screening at transport hubs / vehicles) degree)

[0101] Delivery of inhibitory compounds / anti-adhesion molecules (antibacterial, antiviral, antifungal, antitoxins, etc.) It is also contemplated to provide a device for

[0102] In a laboratory context or elsewhere, embodiments of the present invention may be used in biopharmaceutical and Capture of glycan- and lectin-containing components in purification fractions during pharmaceutical and pharmaceutical processes For example, they can be used to remove LPS / endotoxins and other substances produced during the manufacturing process. This includes the removal of residual microbial matter and contaminants or non-product fractions. Also applicable to recombinant protein / vaccine production to remove major components and concentrate the desired product can.

[0103] The devices and methods of the present invention may be used in conjunction with surgical gloves or other surgical or medical equipment. For example, a device according to the present invention may be applied to the surface of a surgical glove. This reduces the chance of spreading infection during surgery or other care, and is a major source of biocontamination of surgically implanted devices. Use of surgical gloves when handling. Example

[0104] The following non-limiting examples illustrate some embodiments of the present invention.

[0105] Example 1 - Device Fabrication

[0106] To generate active aldehyde groups on the cellulose chains for subsequent attachment of binders, The iodic acid oxidation reaction was carried out. 33 gms of cellulose skeleton of 100% cotton material was mixed with 5.0 m Sodium periodate solution in 0.1 M acetate buffer (1:50 ratio, w / v) at a concentration of 100 mg / ml The cells were immersed in a solution and then oxidized with sodium periodate (Sigma-Aldrich 311448). The mixture was gently stirred at 50 rpm for 6 hours at room temperature for efficient reaction. The reaction was continued in the absence of light while shaking at 400°C. This is thought to occur when two aldehyde groups are formed at the C2 and C3 positions. The compound chosen is 2,3 dialdehyde cellulose (DAC).

[0107] The material was then washed thoroughly with ice-cold distilled water (three washes, 10 times the absorption volume each time) to The periodate oxidant was removed from the treated material. For the addition of proteins, complex carbohydrates, and neo-conjugate carbohydrates, the DAC residues of the cellulose skeleton It is believed that the active ingredient chemically attaches to the binder. The treated cotton material was diluted with the protein solution at a ratio of 1:25 (w / v) The materials were incubated at 4°C for 16 hours, then soaked in PBS at pH 7.4. The mixture was washed three times at 10 times the absorption capacity.

[0108] Example 2 - Biothreat Pathogens

[0109] Recover biothreat pathogens (F. tularensis, Clostridium botulinum, Bacillus anthracis (cells and spores)) The cells were grown to stationary phase and stained for targets. After careful analysis of binding data based on comparison with model organisms, glycoproteins Glycoconjugates and lectins were selected for the preparation of antibacterial cellulose-based devices. The efficacy of the cellulosic wipes (prepared according to Example 1) was tested against the above biothreats. Dry wipes and associated buffers on pathogen-contaminated plastic / metal / glass surfaces This was compared to wipes treated with liquid (dH2O, PBS).

[0110] Contaminants were detected at an OD of 2.0 stained with 0.5% crystal violet. 600 Overnight culture of 100 μl of each contaminant was placed in each selected test area, 5 cm in diameter. Allowed to dry for 60 minutes. For each of the following experiments, the wipe was placed in the center of the contaminated area. After leaving the wipe for 10 minutes, wash with 0.5 ml of PBS pH 7.4. By doing this, the "residual contamination" on each surface is collected, and the bacteria remaining on the surface are counted (measured by optical density). Analysis was performed using a series of quantitative methods for colony count (PCR).

[0111] Regarding Francisella tularensis (Fig. 1), Fetuin glycoprotein (Fig. 1A), asialofetuin glycoprotein (Fig. 1B) Perform efficacy testing as described above using activated wipes containing lectin GNA (Figure 1C). The recovery solution in the appropriate buffer and measurement of the absorbance / optical density at 600 nm (OD600) were added. In addition, residual contamination was monitored. Raw values without surface preparation are shown. Asterisks indicate Statistically different compared to the "no wipe" condition based on Dent's t-test (p<0.05). Data points are shown. Error bars represent standard deviation from triplicate experiments. In some cases, the use of "active" wipes treated with glycoproteins or lectins may be of significant benefit. It can be seen that this results in fewer residual bacteria.

[0112] For Clostridium botulinum (Fig. 2), fetuin glycoprotein (Fig. 2A), asialof Activated wipes containing the etuin glycoprotein (Figure 2B) or the lectin GNA (Figure 2C) The efficacy test was carried out using the appropriate buffer. Residual contamination was monitored by measuring the absorbance / optical density at 1000 kJ / cm2. Raw values without surface conditioning are shown. Asterisks indicate the "no wipe" condition based on Student's t-test (p<0.05). Error bars indicate data points that are statistically different compared to the standard deviation from triplicate experiments. In all but one case, the cells were treated with glycoproteins or lectins. Use of the treated "active" wipes was found to result in significantly fewer residual bacteria. (Figure 2D) is 7.32x10 8 The number of colony forming units (cfu) was measured against the reference strain in cfu / ml. The figures show the residual bacteria present on the surface after the wipe treatment as measured by the recovery. The contaminants were serially diluted, and 100 μl of each was spread onto agar plates to grow the bacteria. Plates with 30-300 colonies were considered an appropriate range for the calculations.

[0113] For B. anthracis (Fig. 3 and Table 4), the ELISA was performed on B. anthracis cells (Fig. 3A) or spores (Fig. 3B). , fetuin glycoprotein, asialofetuin glycoprotein, GNA lectin, G SL-I-B4 lectin, PA-I lectin, AMA lectin, or RCA-1 lectin Efficacy testing was performed using activated wipes containing PEG. Residual contaminants after the wipe treatment were measured at 1 .21x10 7 cfu / ml (vegetative cells) or 1.31x10 7 cfu / ml (spores) The recovered contamination was measured by the recovery of colony forming units (cfu) against the reference strain. The substance was serially diluted and 100 μl of each was spread on an agar plate to grow the bacteria. Plates with 0.00 colonies were considered the appropriate range for calculation. Raw values without surface adjustment Asterisks indicate wipe-free results based on Student's t-test (p<0.05). Error bars indicate data points that are statistically different compared to the original surface. These data are also shown in Table 4 (Table 4-1, Table 4-2) and are presented in Table 4. Surfaces treated with dry wipes (FET—fetuin, ASF—asialof) The percentage of residual contaminants detected compared to the total (etuin) is shown.

[0114] [Table 4-1]

[0115] [Table 4-2]

[0116] The device of the present invention can be used to detect influenza viruses on glass, plastic, and metal surfaces. Briefly, a surface was contaminated with 500 μl of virus solution. The supernatant was spread on the surface and allowed to dry for 3 hours. Fetuin glycoprotein was attached. Wipes or wipes coated with asialofetuin glycoprotein were used. All surfaces were contaminated three times for each type of material. For the wipe test, the wipe was placed in the center of the contaminated area. The wipes were left to interact for 10 minutes. After incubation The wipes were then removed and the contaminated area was assessed for any residue collected. Each surface was rinsed with 1 ml of PBS. Washing, viral RNA isolation and preparation of glass (Figure 4A), plastic (Figure 4B) and gold The collected fluid was transferred to a sterile Eppendorf tube for quantification of residues from the genus (Figure 4C). , the amount of virus isolated from surfaces compared to the amount detected using dry wipes alone. The error bars represent the standard deviation from triplicate experiments. The combined wipes showed that only 2-28% of the virus particles remained after static capture (Table 5). and appeared to reduce residual virus, whereas asialofetuin-conjugated wipes There appeared to be no effect compared to the PBS treated wipes.

[0117] [Table 5]

[0118] Example 3 - Foodborne Pathogens:

[0119] The device of the present invention (prepared according to Example 1) was applied to glass, plastic and metal surfaces. It was also used against the bacteria associated with food poisoning listed above. Table 6 shows the bacteria tested (E. coli O157 :H7 and Enterobacter cloacae), and in each case the leukemia virus bound to a carrier substance. Shows Kuchin.

[0120] [Table 6]

[0121] Figures 5A and 5B show the results of efficacy testing on these bacteria. Similarly, contaminants were prepared from overnight cultures stained with crystal violet. 100 μl of the contaminant was placed on each test area and allowed to dry for 60 minutes. For each, the wipe was placed in the center of the contaminated area and allowed to stand for 10 minutes. The surface preparation was monitored by measuring fluorescence after SYTO82 (Figure 5A, 5B) staining. The raw values are shown without any data. Error bars represent standard deviations from triplicate experiments. The residual fluorescence was measured after 10 minutes of static testing. Based on the assay, only 1% of E. coli O157:H7 was retained on the WGA lectin-activated wipes. The GSI-B4-activated wipes left 4% of the Enterobacter cloacae behind, whereas the GSI-B4-activated wipes left 4% of the Enterobacter cloacae behind. Results showing the effectiveness of the control and active wipes are also shown in Table 7.

[0122] [Table 7]

[0123] Example 4 - Other Skin Pathogens (Bacteria / Fungi):

[0124] Other microorganisms known to colonize the skin may be present in the device of the present invention. These include Propionibacterium spp., Malassezia spp. (formerly Pichia Rosporum), Candida spp., Aspergillus spp., Staphylococcus spp., Len For purposes of illustration, exemplary devices include Staphylococcus sp., Pseudomonas sp., and Haemophilus influenzae. The sachets (prepared according to Example 1) also showed Propionibacterium spp., which is associated with skin diseases and disorders. Used against acnes and Candida albicans.

[0125] Wheat flour bound to the glycoprotein asialofetuin (ASF) and the lectin WGA. Similar to the previous example, the plates were contaminated with Propionibacterium acnes (Figure 6). The static wipe test was carried out again for 10 minutes as in the previous example. After application, 33% residual contaminants were observed on the PBS wipes and 15% on the ASF wipes. 8% of the stains were removed with the WGA wipes, while the WGA wipes only removed 9.5% of the stains with contact alone. It was shown that the staining substance was captured (standing still).

[0126] Wipes conjugated with lectin ConA were used to screen positive cells contaminated with C. albicans (Figure 7). The stain and wipe tests were performed as described above. To compare the capture efficiency at pH 5, 7, and 9, and the standard pH 7.4 buffer solution was used. Wipes were prepared with and without the active ingredient (ConA). The capture effect was observed to be similar over a wide pH range from 5 to 9. The types were equally effective under the selected conditions, and pH changes did not affect the potency of the active ingredients. Ta.

[0127] Example 5 - Wound decontamination and care

[0128] To evaluate the device and its effectiveness for capture from biological surfaces, a pig skin model was used. For the past 20 years, pig skin has become a popular human skin model for studying human skin diseases. The background to this is that pigs and humans have been more successful than any other experimental animals. For example, pig dermal collagen is similar to other collagens in terms of anatomical structure. It is more similar to humans than common laboratory animals. Pig skin is suitable for wound care and sensitization of human diseases. It is well established and studied for use in dye studies. The vascular characteristics and hair follicle types are highly similar to those of human skin. and C. albicans strains were used as target organisms.

[0129] This method is illustrated in Figure 8. Briefly, to remove natural contaminants from the pig skin, The sample was placed in water at 60°C for 30 seconds. 100 μl of E. coli (crystalloid) at OD 2.0 was added. violet stain) or Candida albicans (trypan blue fungal stain) culture solution The solution was dropped onto each pig skin sample using a pipette and left to dry on the skin sample for 30 minutes. The device was subjected to a wipe capture test using static contact for 10 minutes as described above. After the above procedure, 1 ml of LB or yeast medium was added to each pig skin sample, and the contaminant mixture was analyzed. The growth of this mixture was monitored, and E. coli (Figures 9A and B) and C. albicans were detected. The residual amount of the serotonin (Figure 10) was quantified. Figures 9A and 9B show the results of the cotton-based wipe capture assay. Figure 1 shows E. coli recovered from pig skin after screening treatment, and the activated wipes showed a wavelength of 595 nm. WGA lectin was detected by measuring absorbance (Fig. 9A) or colony forming units (Fig. 9B) in the Figure 10 shows the amount of leukocytes recovered from pig skin after the cotton-based wipe capture test procedure. The active wipes showed the presence of C. albicans DSM6659 after a 15-hour growth period. Photometric assay included ConA lectin or GNA lectin.

[0130] Wipes conjugated with lectin ConA were applied to Aspergillus fumigatus-contaminated blotches. The contamination protocol and wipe test were as previously described. A. fumigatus was recovered from pig skin after a cotton-based wipe capture test procedure. The activated wipes were diluted 1:10 with potato-dextrose agar (Figure 11) to remove residual contaminants. After serial dilution and plating, colony forming units were measured and the number of cells containing ConA lectin was After incubation at 30°C for 24 hours, colony count analysis was performed. A. fumigatus Fre recovered from pig skin after ton-based wipe capture testing treatment senius strain 819. The active wipe contained ConA lectin.

Claims

1. 1. A device comprising a carrier material comprising a carbohydrate-based polymer and a binder, the binding agent is attached to the carrier material by one or more covalent bonds; said binding agent being capable of binding to a target; The target is one or more of a biotoxin, a virus, a microorganism, and a microbial component. Devices that are 100% or greater.

2. The device of claim 1 , wherein the carrier material comprises cellulose.

3. 3. The method of claim 1, wherein the carrier material comprises one or more of cotton and paper. device.

4. The carrier material comprises a fluid in which it is dissolved, suspended, dispersed, emulsified, or otherwise carried.

3. The device of claim 1 or 2.

5. the binder is bound to cellulose by one or more covalent bonds. The device according to any one of claims 2 to 4.

6. The binding agent is an antithrombotic agent, an anti-inflammatory agent, an antibody, an antigen, an adhesin, an immunoglobulin, an enzyme , hormones, neurotransmitters, cytokines, proteins, globular proteins, cell adhesion proteins Proteins, peptides, cell attachment peptides, proteoglycans, toxins, polysaccharides, carbohydrates, lipids Fatty acids, drugs, vitamins, DNA segments, RNA segments, nucleic acids, dyes and ligands 6. A device according to any one of claims 1 to 5, comprising one or more of:

7. The binding agent may be one or more of a lectin, a glycoprotein, an oligosaccharide, and a glycoconjugate. The device according to any one of claims 1 to 6, comprising:

8. The device of claim 7 , wherein the binding agent comprises a lectin.

9. The lectin is AIA / Jacalin, RPbAI, AAL, ABL, ACA, A MA, BPA, CAA, Calcepa, CCA, ConA, CPA, DBA, DSA, ECA , EEA, GHA, GNA, GSL-I-B4, GSL-II, HHA, HPA, Lch -A, Lch-B, LEL, LTA, MAA, MOA, MPA, NPA, PA-I, PC A, PHA-E, PHA-L, PNA, PSA, RCA-I / 120, SBA, SJA, SNA-I, SNA-II, STA, UEA-I, VRA, VVA-B4, WFA, and 9. The device of claim 8, wherein the device is one or more of: a WGA; and a WGA.

10. The lectin is VRA, Lch-B, EEA, PA-I, PNA, CAA, GSL- I-B4, AMA, RCA-I / 120, and GNA; The device of claim 9.

11. The device of claim 7 , wherein the binding agent comprises a glycoprotein.

12. The glycoprotein is uromodulin (Tamm-Horsfall protein), Fetuin, asialofetuin, invertase, fibrinogen, α-1-anthraquinone Trypsin, α-crystallin, ceruloplasmin, α-1-acid glycoprotein, RN Ase B, transferrin, β-lactoglobulin, C. -lactalbumin, al casein, B-casein, C-casein, K-casein, lactoferrin, egg albumin , ovomucoid, ovotransferrin, and derivative glycomacropeptide.

12. The device of claim 11, wherein the number of electrodes is 1 or more.

13. The glycoproteins are fetuin, asialofetuin, and α-crystallin.

13. The device of claim 12, wherein the device is one or more.

14. The device of claim 7 , wherein the binder is a glycoconjugate or a neoglycoconjugate.

15. The glycoconjugate or neoglycoconjugate is Blood Group A-BSA, Blood d Group B-HSA, Fuc-α-4AP-BSA, Fuc-β-4AP-BS A, 2'fucosyllactose-BSA, difucosyl-para-lacto-N-hexaose- APD-HSA (Lea / Lex), trifucosyl-Ley-heptasaccharide-AP E-HSA, monofucosyl, monosialyllacto-N-neohexaose-APD-HS A, Gal-β-4AP-BSA, Galα1,3Gal-BSA, Gal-α-1,3 Galb1, Gal-β-1,4Gal-BSA, Gal-α-1,2Gal-BSA, 4GlcNAc-HSA, Gal-α-PITC-BSA, Gal-β-ITC-BSA , Glc-β-4AP-BSA, Glc-β-ITC-BSA, GlcNAc-BSA, Globotriose-HSA, Globo-N-tetraose-APD-HSA, Globotrio ose-APD-HSA, GM1-pentasaccharide-APD-HSA, Asialo- GM1-tetrasaccharide-APD-HSA, globo-N-tetraose-APD-H SA, globotriose APD-HSA, H-type-II-APE-BSA, H-type 2-APE -HSA, Man-α-1,3 (Man-α-1,6), Man-BSA, Man-α- ITC-BSA, Man-b-4AP-BSA, LacNAc-BSA, LacNAc- α-4AP-BSA, LacNAc-β-4AP-BSA, Lac-β-4AP-BSA , lacto-N-tetraose-APD-HSA, lacto-N-fucopentaose I-B SA, lacto-N-neotetraose-APD-HSA, lacto-N-fucopentaose II-BSA, Lacto-N-Fucopentaose III-BSA, Lacto-N-Difco Hexaose I-BSA, Lewis a-BSA, Lewis x-BSA, Lewis is y-tetrasaccharide-APE-HSA, LNDI-BSA / Lewis b- BSA, Di-Lex-APE-BSA, Di-Lewisx-APE-HSA, Tri -Lex-APE-HSA, L-rhamnose-Sp14-BSA, 3' sialyllactose Su-APD-HSA, 3'-sialyl-3-fucosyllactose-BSA, 6'-sialyl Lactose-APD-HSA, Xyl-α-4AP-BSA, Xyl-β-4AP-BS A, 3' sialyl Lewis x-BSA, 3' sialyl Lewis a-BSA, 6-Sulfo Lewis x-BSA, 6-Sulfo Lewis a-BSA, 3-Sulfo Lewis a-BSA, 3-sulfo Lewis x-BSA, sialyl-LNF V-APD-HSA, and sialyl-LNnT-penta-APD-HSA.

15. The device of claim 14, wherein the number of electrodes is 1 or more.

16. The binder is a glycoconjugate, a neoglycoconjugate, or a glycoprotein, and is selected from the group consisting of mannose, N- Acetylglucosamine, N-acetylgalactosamine, N-acetylneuraminic acid, N- Glycolylneuraminic acid (sialic acid), galactose, glucose, and fucose moieties 8. The device of claim 7, having terminal residues comprising one or more of:

17. The device according to any one of claims 1 to 16, wherein the device further comprises an antibacterial substance. Chair.

18. The antimicrobial substance is one or more of a disinfectant, an antibiotic, and a detergent. Item 18. The device according to item 17.

19. 18. The device of claim 17, wherein the antimicrobial agent is silver, copper, or EDTA.

20. The carrier material may be a cloth, wipe, wound dressing, swab, filter, pad, blanket, The device according to any one of claims 1 to 19, in the form of a mat, a mask or a coating. vinegar.

21. Method for removing biotoxins, viruses, microorganisms and / or microbial components from surfaces And, Providing a device according to any one of claims 1 to 20, and contacting the surface with the device; A method comprising:

22. Removal of biotoxins, viruses, microorganisms and / or microbial components from gases or liquids A method of removing Providing a device according to any one of claims 1 to 20, and passing said gas or liquid through said device; A method comprising:

23. The binding agent is capable of binding the biotoxins, viruses, microorganisms and / or bacteria to be removed.

23. The method of claim 21 or 22, wherein the compound binds to a biological component.

24. 10. The method of claim 1, wherein the biotoxin, virus, microorganism and / or microbial component is a spore.

24. The method according to any one of items 21 to 23.

25. 1. A process for manufacturing a device, the method comprising: providing a carrier material comprising a carbohydrate-based polymer; treating the support with an oxidizing agent to generate acid and / or aldehyde groups; and The treated carrier is then coated with one or more binders, the binder being a carbohydrate-based polymer. Covalently bind to one or more of lectins, glycoproteins, and glycoconjugates. contacting the polymer with a binder comprising at least one of:

26. 26. The method of claim 25, wherein the carrier material comprises cellulose.

27. 26. The method of claim 25, wherein the oxidizing agent is a periodate, preferably sodium periodate. Or the method according to 26.

28. The oxidizing agent is 2,2,6,6-tetramethylpiperidine-1-oxyl radical (T EMPO), sodium nitrate or sodium nitrite in phosphoric acid, organic solvent and the presence of base an activator selected from the group consisting of tosyl chloride in the presence of hydroxybenzoates, and combinations thereof; 27. The method of claim 25 or 26.

29. A carrier material comprising cellulose, and uromodulin (Tamm-Horsfall Tan Protein), fetuin, asialofetuin, invertase, fibrinogen, α-1-antitrypsin, α-crystallin, ceruloplasmin, α-1-acid glycoprotein Protein, RNAse B, transferrin, β-lactoglobulin, C. -lactal albumin, B-casein, C-casein, K-casein, lactoferrin, egg White albumin, ovomucoid, ovotransferrin, and derivatives glycomacropeptide a binding agent comprising one or more glycoproteins selected from the group consisting of There was, the binder is bound to the cellulose by one or more covalent bonds; said binding agent being capable of binding to a target; The target may be one or more of a biotoxin, a virus, a microorganism, and a microbial component. The device is more than

Images